Matching patients to clinical trials using AI-powered analysis
5 trials available for patient matching • Selected: Novel GLP-1 Agonist for Type 2 Diabetes
Protocol ID
CT-2024-DM-001
Research Aim
Evaluate efficacy and safety of investigational GLP-1 receptor agonist in reducing HbA1c levels and promoting weight loss in adults with Type 2 diabetes inadequately controlled on metformin monotherapy.
Demographics
Age: 18-65 years
Gender: Male, Female
Key Conditions: Type 2 Diabetes Mellitus, HbA1c 7.0-10.5%...
Protocol ID
CT-2024-CV-018
Research Aim
Evaluate the efficacy and safety of monthly extended-release naltrexone in combination with a brief, manualized CBT intervention (4 sessions) to reduce heavy drinking days and improve functioning in adults who engage in stress-triggered hazardous drinking with comorbid anxiety/depressive symptoms.
Demographics
Age: 20-65 years
Gender: Male, Female
Key Conditions: Moderate Alcohol Use Disorder (DSM-5) or hazardous episodic heavy drinking (≥4 heavy drinking days in past 30 days), Self-reported stress-triggered drinking related to work/family stressors...
Protocol ID
CT-2024-NASH-005
Research Aim
Compare the efficacy and safety of an investigational oral Factor XIa inhibitor (FXIaX) to standard-of-care direct oral anticoagulant (DOAC) therapy for reduction of recurrent venous thromboembolism (VTE) and major bleeding in adults presenting with acute symptomatic pulmonary embolism (PE).
Demographics
Age: 18-70 years
Gender: Male, Female
Key Conditions: Confirmed acute symptomatic pulmonary embolism on imaging (CT pulmonary angiography or V/Q) within 72 hours of randomization, May have concomitant symptomatic proximal deep vein thrombosis (DVT)...
Protocol ID
CT-2024-RA-042
Research Aim
Assess and document clinical features of sudden-onset positional vertigo and evaluate response to positional maneuvers such as the Epley maneuver.
Demographics
Age: 18-75 years
Gender: Male, Female
Key Conditions: Acute onset vertigo, Positional dizziness triggered by head movement...
Protocol ID
CT-2024-AD-029
Research Aim
Determine whether monthly IV infusions of anti-amyloid-beta monoclonal antibody can slow cognitive decline measured by CDR-SB in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease with confirmed amyloid pathology.
Demographics
Age: 50-85 years
Gender: Male, Female
Key Conditions: MCI or mild AD dementia, Positive amyloid PET scan...
5 of 6 patients match trial criteria
MRN-2024-001
High Eligibility
Age
45 years
Gender
Female
Last Visit
11/10/2024
Add this patient to the enrollment pipeline
No assessment available for this patient-trial combination
Select a different trial or patient to view cached assessments